Amal K. Hussein

1.7k total citations · 2 hit papers
33 papers, 1.4k citations indexed

About

Amal K. Hussein is a scholar working on Pharmaceutical Science, Public Health, Environmental and Occupational Health and Molecular Biology. According to data from OpenAlex, Amal K. Hussein has authored 33 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pharmaceutical Science, 8 papers in Public Health, Environmental and Occupational Health and 6 papers in Molecular Biology. Recurrent topics in Amal K. Hussein's work include Advancements in Transdermal Drug Delivery (13 papers), Advanced Drug Delivery Systems (12 papers) and Ocular Surface and Contact Lens (7 papers). Amal K. Hussein is often cited by papers focused on Advancements in Transdermal Drug Delivery (13 papers), Advanced Drug Delivery Systems (12 papers) and Ocular Surface and Contact Lens (7 papers). Amal K. Hussein collaborates with scholars based in Egypt, Japan and Saudi Arabia. Amal K. Hussein's co-authors include Hatem A. Sarhan, Taro Shimizu, Tatsuhiro Ishida, Eman Alaaeldin, Omar H. El-Garhy, Amr S. Abu Lila, János Szebeni, Raid G. Alany, Heba F. Mansour and Hidenori Ando and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of Controlled Release and International Journal of Pharmaceutics.

In The Last Decade

Amal K. Hussein

31 papers receiving 1.4k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

PEGylated liposomes: immunological responses

2019 384 citations Taro Shimizu, Amal K. Hussein et al. profile →
Polyethylene glycol (PEG): The nature, immunogenicity, and role in the hypersensitivity of PEGylated products

2022 286 citations Mohamed Yousif Ibrahim, Eslam Ramadan et al. Journal of Controlled Release profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amal K. Hussein Egypt	16	500	482	386	194	180	33	1.4k
Olga Kammona Greece	22	506 1.0×	633 1.3×	288 0.7×	199 1.0×	184 1.0×	44	1.6k
Shivani Rai Paliwal India	21	566 1.1×	570 1.2×	539 1.4×	371 1.9×	149 0.8×	37	1.6k
Ashwni Verma India	27	774 1.5×	411 0.9×	456 1.2×	393 2.0×	173 1.0×	65	2.0k
Abdulaziz Mohsen Al-mahallawi Egypt	22	386 0.8×	852 1.8×	241 0.6×	141 0.7×	214 1.2×	45	1.6k
Rajeev K. Tyagi India	26	615 1.2×	748 1.6×	501 1.3×	214 1.1×	190 1.1×	70	2.0k
Yıldız Özsoy Türkiye	24	325 0.7×	862 1.8×	363 0.9×	217 1.1×	149 0.8×	82	1.8k
Yuehong Xu China	23	382 0.8×	793 1.6×	200 0.5×	139 0.7×	161 0.9×	46	1.4k
Asim Ur Rehman Pakistan	16	289 0.6×	530 1.1×	392 1.0×	297 1.5×	92 0.5×	43	1.4k
Srividya Gorantla India	27	349 0.7×	880 1.8×	245 0.6×	165 0.9×	260 1.4×	38	1.7k
M.E.M. Cruz Portugal	27	752 1.5×	363 0.8×	392 1.0×	184 0.9×	330 1.8×	57	1.9k

Countries citing papers authored by Amal K. Hussein

Since Specialization

Citations

This map shows the geographic impact of Amal K. Hussein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amal K. Hussein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amal K. Hussein more than expected).

Fields of papers citing papers by Amal K. Hussein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amal K. Hussein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amal K. Hussein. The network helps show where Amal K. Hussein may publish in the future.

Co-authorship network of co-authors of Amal K. Hussein

This figure shows the co-authorship network connecting the top 25 collaborators of Amal K. Hussein. A scholar is included among the top collaborators of Amal K. Hussein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amal K. Hussein. Amal K. Hussein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fathalla, Zeinab, et al.. (2025). Ellagic acid-loaded chitosan nanoparticles as an approach for mitigating oxidative stress and liver damage in Poloxamer-407-induced hyperlipidemia in mice: Development and optimization through 3 level full factorial design. International Journal of Pharmaceutics. 677. 125659–125659. 3 indexed citations

Alotaibi, Badriyah S., Mahmoud M. A. Elsayed, Manal E. Alosaimi, et al.. (2023). Characterization and Bio-Evaluation of the Synergistic Effect of Simvastatin and Folic Acid as Wound Dressings on the Healing Process. Pharmaceutics. 15(10). 2423–2423. 4 indexed citations

Ibrahim, Mohamed Yousif, Taro Shimizu, Hidenori Ando, et al.. (2023). Investigation of anti-PEG antibody response to PEG-containing cosmetic products in mice. Journal of Controlled Release. 354. 260–267. 31 indexed citations

Aboud, Heba M., et al.. (2022). Tailoring of Selenium-Plated Novasomes for Fine-Tuning Pharmacokinetic and Tumor Uptake of Quercetin: In Vitro Optimization and In Vivo Radiobiodistribution Assessment in Ehrlich Tumor-Bearing Mice. Pharmaceutics. 14(4). 875–875. 23 indexed citations

Hussein, Amal K., et al.. (2022). Efficacy of Ezetimibe as Monotherapy in Hypercholesterolemic Patients with and without Diabetes: A Randomized Controlled Clinical Trial. The Egyptian Journal of Hospital Medicine. 88(1). 2942–2947.

Ibrahim, Mohamed Yousif, Eslam Ramadan, Nehal E. Elsadek, et al.. (2022). Polyethylene glycol (PEG): The nature, immunogenicity, and role in the hypersensitivity of PEGylated products. Journal of Controlled Release. 351. 215–230. 286 indexed citations breakdown →

Shimizu, Taro, Nehal E. Elsadek, Sherif E. Emam, et al.. (2021). Incorporating Gangliosides into PEGylated Cationic Liposomes that Complexed DNA Attenuates Anti-PEG Antibody Production but Not Anti-DNA Antibody Production in Mice. Molecular Pharmaceutics. 18(6). 2406–2415. 8 indexed citations

Hussein, Amal K., et al.. (2020). Real Life Egyptian Experience of Daclatasvir Plus Sofosbuvir with Ribavirin in Naïve Difficult to Treat HCV Patients. Infectious Disorders - Drug Targets. 20(1). 43–48. 6 indexed citations

Hussein, Amal K., et al.. (2020). A Novel Nanoemulsion Intermediate Gel as a Promising Approach for Delivery of Itraconazole: Design, In Vitro and Ex Vivo Appraisal. AAPS PharmSciTech. 21(7). 272–272. 15 indexed citations

10.

Mohammed, Ahmed Fouad Abdelwahab, Taishi Higashi, Keiichi Motoyama, et al.. (2019). In Vitro and In Vivo Co-delivery of siRNA and Doxorubicin by Folate-PEG-Appended Dendrimer/Glucuronylglucosyl-β-Cyclodextrin Conjugate. The AAPS Journal. 21(4). 54–54. 19 indexed citations

11.

Elsayed, Mahmoud M. A., et al.. (2019). Response Surface Methodology as a Useful Tool for Development and Optimization of Sustained Release Ketorolac Tromethamine Niosomal Organogels. Journal of Pharmaceutical Innovation. 15(4). 664–677. 15 indexed citations

12.

Mohammed, Ahmed Fouad Abdelwahab, Taishi Higashi, Keiichi Motoyama, et al.. (2018). Targeted siRNA delivery to tumor cells by folate-PEG-appended dendrimer/glucuronylglucosyl-β-cyclodextrin conjugate. Journal of Inclusion Phenomena and Macrocyclic Chemistry. 93(1-2). 41–52. 5 indexed citations

13.

Ibrahim, Mohamed M., et al.. (2018). Best tigecycline dosing for treatment of infections caused by multidrug-resistant pathogens in critically ill patients with different body weights. Drug Design Development and Therapy. Volume 12. 4171–4179. 12 indexed citations

14.

Khames, Ahmed, et al.. (2018). Hydralazine HCl rapidly disintegrating sublingual tablets: simple dosage form of higher bioavailability and enhanced clinical efficacy for potential rapid control on hypertensive preeclampsia. Drug Design Development and Therapy. Volume 12. 3753–3766. 9 indexed citations

15.

Hussein, Amal K., et al.. (2016). Flurbiprofen-loaded niosomes-in-gel system improves the ocular bioavailability of flurbiprofen in the aqueous humor. Drug Development and Industrial Pharmacy. 43(6). 902–910. 55 indexed citations

16.

Hussein, Amal K., et al.. (2016). Formulation and clinical evaluation of silymarin pluronic-lecithin organogels for treatment of atopic dermatitis. Drug Design Development and Therapy. 10. 1101–1101. 50 indexed citations

17.

Fathalla, Zeinab, Khaled A. Khaled, Amal K. Hussein, Raid G. Alany, & A. Vangala. (2015). Formulation and corneal permeation of ketorolac tromethamine-loaded chitosan nanoparticles. Drug Development and Industrial Pharmacy. 42(4). 514–524. 42 indexed citations

18.

Ahmed, Osama A. A., et al.. (2015). Improved corneal bioavailability of ofloxacin: biodegradable microsphere-loaded ion-activated in situ gel delivery system. Drug Design Development and Therapy. 9. 1427–1427. 23 indexed citations

19.

Abdelkader, Hamdy, Sayed Ismail, Amal K. Hussein, et al.. (2012). Conjunctival and corneal tolerability assessment of ocular naltrexone niosomes and their ingredients on the hen's egg chorioallantoic membrane and excised bovine cornea models. International Journal of Pharmaceutics. 432(1-2). 1–10. 78 indexed citations

20.

El-Menshawe, Shahira F. & Amal K. Hussein. (2011). Formulation and evaluation of meloxicam niosomes as vesicular carriers for enhanced skin delivery. Pharmaceutical Development and Technology. 18(4). 779–786. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact